Cite

HARVARD Citation

    Cui, J. et al. (2020). Oral versus intravenous palonosetron in Chinese cancer patients receiving moderately emetogenic chemotherapy: A non‐inferiority phase III trial. European journal of cancer care. p. n/a. [Online]. 
  
Back to record